Psoriasis is a common skin disease that presents with well-demarcated patches of inflammation. Recurrent disease in fixed areas of the skin indicates a localized disease memory that is preserved in resolved lesions. In line with such concept, the involvement of tissue-resident immune cells in psoriasis pathology is increasingly appreciated. Langerhans cells (LCs) are perfectly placed to steer resident T cells and local tissue responses in psoriasis. Here, we present an overview of the current knowledge of LCs in human psoriasis, including findings that highlight pro-inflammatory features of LCs in psoriasis lesions. We also review the literature on conflicting data regarding LC localization and functionality in psoriasis. Our review highlights that further studies are needed to elucidate the molecular mechanisms that drive LCs functionality in inflammatory diseases.

Keywords: Langerhans cells, human, psoriasis, microenvironment, inflammation, Langerhans cell function, Langerhans cell localization

SELF-RENEWING LCs FORM A CELLULAR NETWORK IN HEALTHY EPIDERMIS

The human skin forms a sophisticated barrier in which resident immune cells orchestrate immune responses against foreign antigens, while maintaining tolerance to commensals (1). In focal inflammatory skin diseases, tissue homeostasis is unevenly disturbed, and patches of intense inflammation are surrounded by apparently normal skin. Local alterations of resident immune cells are increasingly appreciated in these diseases. Langerhans cells (LCs) form a stable pool of professional antigen-presenting cells resident in healthy epidermis with distinct ontogeny and phenotypes compared to dermal dendritic cells (DCs) (2, 3). The CFS-1 receptor ligand IL-34, abundantly produced by keratinocytes, is crucial for LC development within the skin (4), whereas LC residency is strongly dependent on the constitutive expression of TGF-β (5). In contrast, replenishment of dermal subsets of DCs is dependent on the differentiation of circulating precursors and is driven by the tyrosine kinase FLT3 ligand (6, 7). LCs predominately self-renew within murine (8) and human skin, with donor-derived LCs detected up to 10 years after human hand transplantation (9, 10). However, in murine models of inflammation and infection, short-lived and bone marrow-derived CCR2-expressing myeloid precursors fill up the epidermal niche following LC depletion, indicating heterogeneity within the pool of LCs in resolved skin lesions (8, 11). Human LCs form a network capable of sensing the entire skin surface (12) and comprise 2–4% of epidermal cells with a surface density of 500–1,000 cells per mm² (13, 14). Apart from their ability to sense danger and present antigens, the function of human LCs remains debated after more than a century of studies in healthy and diseased conditions.
Functional studies in murine models have provided fundamental insights into LC biology in different settings of tissue immunity and inflammation. However, profound anatomical and immunological differences are obvious when comparing murine and human skin. Human epidermis comprises several layers of keratinocytes (14) and is dominated by interfollicular epithelium, whereas murine epidermis comprises 2–3 cell layers and is covered by dense hair follicles (1). Although many aspects of LC biology and functionality are comparable between mouse and man (15), epidermal lymphocyte populations differ, with γδ T cells populating human epidermis and dendritic epidermal T cells and γδ T cells dominating the murine epidermis (16). Finally, albeit inflammatory models have provided valuable information on LC biology, the full complexity of human inflammatory skin diseases cannot be captured in murine models (17).

**PSORIASIS OCCURS IN FIXED PATCHES OF THE SKIN**

Psoriasis is one example of a focal inflammatory skin disease where disturbance of LC biology has been reported. Psoriasis affects 2–3% of the human population and typically presents with macroscopic well-demarcated, red, and scaly plaques. Genetic predisposition increases the risk of psoriasis (18), and several psoriasis-associated genes are linked to the immune system. In particular, HLA-Cw6 is strongly associated with psoriasis and genome-wide association studies link psoriasis to polymorphisms of genes belonging to MHC class I pathway (ERAP1), IL-23 signaling pathway (IL12B, IL23A, and IL23R), cytokines pathways and Th17 polarization (STAT3), or NF-kB pathway (CARD14) (19). Epidermal hyperplasia, focal immune cell infiltration, and vascular changes dominate the microscopic disturbances in affected sites, whereas non-lesional and resolved skin at large appears normal. Contemporary immunological findings support the idea that psoriasis plaques are maintained by interactions between aberrantly differentiated keratinocytes and immune cells, both resident and recruited. Myeloid and lymphoid immune cells including T cells, innate lymphoid cells, inflammatory DCs, and neutrophils accumulate in psoriasis lesions and produce disease-driving effector molecules such as IL-23, TNF, IL-17, IL-22, granzyme A, and IFN-γ in situ (20–34). Both genetic and therapeutic studies imply that cytokines originating from DCs are involved in psoriasis pathogenesis. The influx of several subsets of inflammatory DCs into psoriasis lesions is discussed in several recent reviews (35, 36). In contrast, few studies have characterized LCs in psoriasis. Nevertheless, these few studies have shed some light on the complexity and plasticity of human LCs. As of yet, less can be concluded regarding pathologic consequences of such LC alterations.

**MICROENVIRONMENTAL ALTERATIONS ASSOCIATED WITH PSORIASIFORM INFLAMMATION IMPACT ON LC FUNCTIONALITY**

LCs sense the external environment and the microbiota covering the human body through dendrites protruding all the way to the apical part of epidermis (12). Compared to dermal DCs, LCs express fewer Toll-like receptors (TLRs) (37–39), which indicates impaired capacity to respond to TLR signaling (39). It is plausible that LCs maintain tolerance to commensals during homeostatic conditions (40). Within psoriasis lesions, LCs are exposed to a complex plethora of inflammatory signals that might affect the expression pattern and the activation threshold of TLRs. In contrast to atopic dermatitis, the few available reports on the psoriasis microbiome have not been able to highlight striking alterations from healthy skin (41–45). Higher resolution analysis using shotgun metagenomics, ideally combined with genetic and transcriptomic analysis, may shed light on psoriasis dysbiosis. It would be of particular interest to investigate the fungal microbiome in psoriasis, taken that IL-17 is associated with fungal responses (46). Another source of external influence on LCs functionality is systemic medication. Angiotensin II inhibitors, a common treatment for hypertension, dampen TGF-β signaling and reduce the density of LCs in human skin (5). In a number of case reports, losartan is implicated as a triggering factor for psoriasis (47, 48), and it would be interesting to investigate the activation status and functionality of LCs in such patients.

Activated keratinocytes represent another LC-trigger in the skin milieu (49, 50). Both keratinocytes and T cells secrete the psoriasis triggering cytokine granulocyte–macrophage colony-stimulating factor (GM-CSF) (51). GM-CSF induces LC maturation and exacerbates their stimulatory capacity (52). It is plausible that activated keratinocytes interact with LCs in evolving psoriasis lesions. In psoriasis plaques, keratinocytes upregulate the antimicrobial peptide LL-37 (53) that theoretically should activate LCs (54). Activated LCs could potentially present antigens in situ to T cells infiltrating the skin. IL-22 and IL-17 produced by T cells in psoriasis plaques amplify the production of the antimicrobial peptide LL-37 in keratinocytes (55), thereby perpetuating this potential inflammatory loop (Figure 1).

**ALTERED LOCALIZATION OF LCs WITHIN PSORIASIS LESION**

Conflicting data regarding the density of LCs in psoriasis have been debated since the seventies with reports detecting increased (57, 59, 60), decreased (61–63), or stable (22, 31, 64–66) densities of LCs in psoriasis-affected epidermis. Interindividual variation in LC density is considerable in healthy and psoriasis-affected subjects, and thus, the variable results may be a consequence of underpowered studies. In addition, local redistribution of LCs and shared surface markers with inflammatory DCs complicate the assessment of LC density within psoriasis plaques. In active psoriasis, LCs co-localize with T cells and inflammatory DCs in epidermal aggregates and relocate within epidermis to the basement membrane and to the apical part of the dedifferentiated epidermis (Figures 2A–C) (67). To add a further layer of complexity, increased density of LCs in perilesional skin, close to the border of active psoriasis lesions, has been reported (60, 68, 69), and the conflicting results obtained by different investigators might be affected by the location within the psoriatic lesion that was sampled. Increased (60, 64, 68) or similar (70) numbers of LCs in non-involved psoriasis skin in comparison to healthy skin...
Figure 1 | Langerhans cells (LCs) cross-talk with keratinocytes and T cells within psoriasis plaques. Environmental triggers such as altered microbiota, necrotic cells or antimicrobial peptides (AMPs) activate LCs to produce IL-15, IL-23 (31, 56), CXCL9, CXCL10, and CCL20 (57). IL-15 and IL-23 induce T cell activation of IL-22 and IL-17. CXCL9, CXCL10, and CCL20 are chemotactic molecules important for further lymphocyte recruitment.

In contrast, LCs derived from atopic dermatitis preferentially expressed CCL17 and CCL20, underlying the disease specificity of LC function. In a recent publication, a subset of myeloid cells expressing CD5 promoting induction of IL-22, IFNγ, TNF, and granzyme B in mixed lymphocyte reaction assays was enriched in psoriasis epidermis (84). We and others have directly shown that LCs from psoriatic lesions produce IL-23 following TLR activation (31, 56), thereby directly linking LCs to the pathogenic IL-23/IL-17 axis. Conversely, lesional LCs also display increased mRNA levels for several tolerogenic factors, including IDO-1, PD-L1, and PD-L2 (31), which complicates interpretations of their role in chronic psoriasis plaque. New techniques are needed to fully understand the overall role of LCs in psoriasis, but current data point toward an active participation in shaping the local inflammatory milieu (Figure 1).

Functional studies on human LCs in psoriasis lesions are scarce in comparison to the wealth of studies that have investigated the properties of blood-derived lesional immune cells. In line with the pro-inflammatory microenvironment within the psoriasis lesions (83), and despite the tolerogenic potential of LCs in healthy skin (40), LCs seem to play an active role in sustaining the inflammation in psoriasis. Transcriptional profiling of LCs sorted from lesional psoriasis revealed expression of several immune cell attracting chemokines including CXCL1 and CXCL10 and inflammatory chemokines such as CCL18 and CCL20 (57).

Local Antigen Presentation in Psoriasis Lesions

Systemic administration of T cell-depleting antibodies temporally normalizes psoriasis pathology in human patients (85). Epidermal T cells accumulate (86, 87) and co-localize with both LCs and inflammatory DCs within psoriasis lesions (Figure 2B) (31). The impressive inflammatory profile of epidermal T cells (30, 33, 34, 88) could result from in situ stimulation by epidermal LCs and DCs. Indeed, several studies have shown that DCs derived from psoriasis lesions sustain the inflammation by producing TNF, iNOS, and IL-23 (20, 22–24, 26, 29, 35, 75). Furthermore, lesional DCs are capable of activating allogenic T cells and induce production of IL-17, IL-22, and IFN-γ (29, 57, 80, 89). Intriguingly, LCs from psoriasis skin show similar ability to stimulate allogenic T cells compared to LCs sorted from atopic dermatitis-affected skin (57). Several autoantigens are proposed to be important to maintain psoriasis (53, 90–92), but the polyclonal pool of pro-inflammatory T cells in psoriasis plaques complicates the concept of psoriasis as a purely autoimmune disease (92, 93). Lipid antigens are presented by CD1a, highly expressed on LCs and on inflammatory DCs. The presence of...
CD1a-restricted T cells polarized to IL-17 and IL-22 production in lesional psoriasis (91) is indicative of in situ antigen presentation of LCs to T cells, but formal proof of such events remains to be shown in human settings.

**LCs IN RESOLVED SKIN SHOW POTENTIAL TO MAINTAIN PATHOGENIC RESIDENT T CELLS**

Therapies for psoriasis range from topical treatments to UV therapy and systemic immunomodulatory treatments. Biologics targeting cell-to-cell signaling through TNF or the IL-23/IL-17 pathway have revolutionized the clinical management of severe psoriasis. This range of different treatment strategies offers a possibility to investigate LC biology in different settings of resolved psoriasis (94, 95). UV light induces LC migration from the epidermis, and a reduction in the number of LCs in the skin has been noted after UV treatment (59, 72). TNF inhibitors alter the balance of resident and infiltrating DCs in both epidermis and dermis (69, 73, 74). Despite complete resolution of macroscopic disease, the local transcriptome remains dysregulated following both UVB and anti-TNF treatment (96, 97), and resident T cells poised to produce IL-17A and IL-22 accumulate in resolved lesions (30, 88). LCs sorted from resolved lesions after successful treatment with UVB therapy retain elevated IL15 expression, whereas LCs from anti-TNF-treated lesions display residual IL23 expression. Furthermore, LCs sorted from resolved lesions during TNF treatment, unlike healthy LCs, are able to respond to TLR stimulation with IL-23 production (31). These findings, together with their placement in close contact with T cells within active lesions (Figure 2B), put LCs both in the right place and perfectly equipped to induce IL-17 and IL-22 production in IL-23R-positive epidermal resident T cells (88).

**LESSONS LEARNT FROM LC BIOLOGY IN MURINE MODELS OF PSORIASIS**

Psoriasis is restricted to the human species; nevertheless, several murine models have been developed to mimic psoriasiform inflammation (17). These models provide an attractive tool to further explore findings from human studies in an in vivo setting (Table 1). Several mouse models support the idea that LCs have a pathogenic role in acute disease. In early studies using the flaky skin mouse, where mice develop scaling and vessel abnormalities...
TABLE 1 | Alteration of LCs in human psoriasis and in mouse models.

| LCs                               | Observed effect                  | Observation in humans                                      | Observation in murine models                        | Mouse model         |
|-----------------------------------|----------------------------------|-------------------------------------------------------------|------------------------------------------------------|---------------------|
| Phenotype                         | Epidermal density of LCs         | Increase                                                    | Baker et al. (69), Komine et al. (60), Fujita et al. (57) | Sundberg et al. (98), Schön et al. (99), Singh et al. (105), Xiao et al. (101) | Flaky skin mouse, IL-23 injection, IMQ |
|                                   |                                  | Decrease                                                    | Lisa (63), Bos et al. (61), Glitzner et al. (62)     | Suzuki et al. (100), Glitzner et al. (62)                | IMQ                 |
|                                   |                                  | Stable                                                      | Gommans et al. (65), Czernielewski et al. (64), Gunther et al. (66), Martini et al. (31) |                        | –                   |
|                                   | IL-23 and inflammatory chemokines production | Fujita et al. (57), Sweeney et al. (56), Martini et al. (31) | Yoshiki et al. (102), Sweeney et al. (56), Xiao et al. (101) | IMQ                 |
|                                   | IL-10 and PD-L1 expression       | –                                                           | Glitzner et al. (62)                                  | DKO*                |
| Function                          | Migratory capacity               | Increased                                                   | Suzuki et al. (100), Glitzner et al. (62), Xiao et al. (101) | IMQ, DKO*           |
|                                   |                                  | Impaired                                                    | Cumberbatch et al. (70), Shaw et al. (76)              | –                   |
|                                   | Enhanced T cell stimulatory ability | Fujita et al. (57)                                         | Yoshiki et al. (102), Xiao et al. (101)               | IMQ                 |
| dDCs                              | Observed effect                  | Observation in humans                                      | Observation in murine models                        | Mouse model         |
| Phenotype                         | Density of dDCs                  | Increase                                                    | Summarized by Haniffa et al. (63), Jariwala (35), Kim et al. (36) | Glitzner et al. (62), van der Fits (107), Terhorst et al. (81), Singh et al. (105) | DKO*, IMQ, IL-23 injection |
|                                   | Pro-inflammatory cytokine profile (production of IL-23, TNF, iNOS) | Wohn et al. (106), Massot et al. (103), Singh et al. (105) | IMQ, IL-23 injection                                  |                     |
| Function                          | Enhanced T cell stimulatory ability | Wohn et al. (106), Massot et al. (103)                      | IMQ                                                   |                     |

LC, Langerhans cell.

as a consequence of an autosomal recessive mutation of the Ttc7 gene, the number of LCs increases in acute disease (98) and is reduced after administration of an IL-1p-neutralizing antibody (99). In the IMQ model, the density of epidermal LCs is reduced and coupled with enhanced LC emigration to the skin-draining lymph nodes (100). More strikingly, data from IMQ-induced psoriasiform inflammation show that LCs produce pro-inflammatory cytokines necessary to activate pathogenic T cells (56, 101, 102), whereas other studies focus on the role of dermal DCs in driving psoriasiform inflammation (103– 106). Conversely, recent work attribute LCs a protective role with elevated levels of IL-10 mRNA and upregulation of PD-L1 in the Jun<sup>p</sup> JunB<sup>B</sup> K5cre<sup>AP</sup> (DKO*) mouse (62). Moreover, after long-term application of IMQ, LCs are important to control the influx of neutrophils into the epidermis (81), indicating that LCs relocated to the border between epidermis and dermis may act as gate keepers that influence on epidermal tissue homeostasis. Collectively, it appears that the lack of clarity on LCs in human psoriasis is mirrored in the mouse models.

**CHALLENGES IN PHENOTYPIC AND FUNCTIONAL STUDIES OF LC IN PSORIASIS PATHOGENESIS**

Characterization of LCs in psoriasis lesions was initially performed by immunohistochemistry using markers such as HLA-DR, CD1a, and s100 proteins (59, 61, 108, 109). However, inflammatory epidermal DCs share many of the cellular markers previously used to define LCs (22, 31, 57). In humans, in both healthy skin and inflamed skin, the most reliable markers for epidermal LCs are Birbeck granules and Langerin. Langerin has an extracellular domain and an intracellular domain located within the Birbeck granules (110), therefore choosing the right antibody is essential to optimize cell sorting. Although low expression of CD1a is detected on inflammatory DCs, flow cytometry can separate CD1a-bright LCs and CD1a-dim inflammatory DCs. Despite reliable protocols to sort LCs ex vivo (111), functional studies require substantial numbers of viable cells which complicate the analysis of clinical material. Decreased LC viability following tissue isolation procedures or even short-term culture (112–114) further impedes the study of human LC functionality. Instead, LC-like cells differentiated from blood CD34<sup>+</sup> precursors have been used. Although these cells share some properties with primary LCs, they display a mature phenotype (115) with profound differential transcriptomic profiles (116). It is important to bear these methodologic challenges in mind when assessing the wealth of sometimes conflicting reports on LC biology.

**CONCLUSION AND FUTURE PERSPECTIVES**

In psoriasis lesions, LCs relocate both within the epidermis and to the dermis. Their localization in close contact with lesional T cells indicates that LCs may participate in focal immunopathology. Indeed, LCs are poised to produce IL-23 in active and resolved psoriasis lesions. However, despite considerable efforts in a multitude of models and settings, the role of LCs in psoriasis pathogenesis remains to be shown. With the current speed of development of experimental techniques combined with the wealth of novel immunotherapies, ample opportunities to fully elucidate the involvement of LCs in psoriasiform inflammation should present themselves over the years to come.
AUTHOR CONTRIBUTIONS

LE and EM planned the outline, reviewed the literature, and wrote this paper together. EM prepared figures and tables.

REFERENCES

1. Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol* (2014) 14:289–301. doi:10.1038/nri3646
2. Ginhoux F, Merad M. Ontogeny and homeostasis of Langerhans cells. *Immunol Cell Biol* (2010) 88:387–92. doi:10.1038/icb.2010.38
3. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annua Rev Immunol* (2013) 31:563–604. doi:10.1146/annurev-immunol-020711-074950
4. Wang Y, Colonna M. Interkeukin-34, a cytokine crucial for the differentiation and maintenance of tissue resident macrophages and Langerhans cells. *Eur J Immunol* (2014) 44:1575–81. doi:10.1002/eji.20134365
5. Mohammed J, Beura LK, Bobr A, Astyr B, Chicoine B, Khamwet S, et al. Stromal cells control the epithelial residence of DCs and memory T cells by regulated activation of TGF-beta. *Nat Immunol* (2016) 17:414–21. doi:10.1038/ni.3396
6. Haniffa M, Gunawan M, Jardine L. Human skin dendritic cells in health and disease. *J Dermatol Sci* (2015) 77:85–92. doi:10.1016/j.jdermsci.2014.08.012
7. Breton G, Lee J, Zhou YJ, Schreiber JJ, Keler T, Puhr S, et al. Circulating progenitors of human CD103+ and CD141+ dendritic cells. *J Exp Med* (2015) 212:401–13. doi:10.1084/jem.20141441
8. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. Reversal of epidermal Langerhans’ cells renew in the skin throughout life under steady-state conditions. *Nat Immunol* (2002) 3:1135–41. doi:10.1038/ni852
9. Kanitakis J, Morelon E, Petruzzo P, Badet L, Dubernard JM. Self-renewal capacity of human epidermal Langerhans cells: observations made on a composite tissue allograft. *Exp Dermatol* (2011) 20:145–6. doi:10.1111/j.1600-0625.2010.01146.x
10. Kanitakis J, Petruzzo P, Dubernard JM. Turnover of epidermal Langerhans’ cells. *N Engl J Med* (2004) 351:2661–2. doi:10.1056/NEJM200412163512523
11. Eidsmo L, Allan R, Caminschi I, van Rooijen N, Heath WR, Carbone FR. Langerhans cells in Psoriasis: Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol* (2011) 11:797–807. doi:10.1038/nri3076
12. Kubo A, Nagao K, Yokouchi M, Sasaki H, Amagai M. External antigen uptake of human skin dendritic cells and macrophages. *J Invest Dermatol* (2013) 133:1184–93. doi:10.1038/jid.2013.05036

FUNDING

This work was funded by grants from Vetenskapsrådet, Marcus and Marianne Wallenbergs Stiftelse, Psoriasisfondén and Gösta Karlssons Minnesfond, Ragnar Söderbergs Stiftelse.

21. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. *Immunity* (2011) 35:596–610. doi:10.1016/j.immuni.2011.08.001
22. Guttmann-Yasky E, Lowes MA, Fuentes-Duculan J, Whynot J, Novitskaya I, Cardinale I, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. *J Allergy Clin Immunol* (2007) 119:1210–7. doi:10.1016/j.jaci.2007.03.006
23. Hansel A, Gunther C, Ingwerson J, Starke J, Schmitz M, Bachmann M, et al. Human slan (6-sulfo LacNac) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. *J Allergy Clin Immunol* (2011) 127:787–94 e1–e9. doi:10.1016/j.jaci.2010.12.009
24. Lee E, Treptich W, Oestreicher JL, Pittman D, Wang F, Chiaman F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med* (2004) 199:125–30. doi:10.1084/ jem.20030451
25. Lin AM, Rubin CJ, Kandpur R, Wang JY, Riblett M, Yalavartih S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. *J Immunol* (2011) 187:490–500. doi:10.4049/jimmunol.1100123
26. Teunissen MB, Zheng L, de Groot M, de Rie MA, Fine JS, Chen SC. Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. *Arch Dermatol Res* (2012) 304:443–9. doi:10.1007/s00403-012-1231-7
27. Teunissen MBM, Munnske JM, Bernink JH, Spuls PI, Res PCM, Te Velde A, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+)+ ILC3 in lesional skin and blood of psoriasis patients. *J Invest Dermatol* (2014) 134:2351–60. doi:10.1038/jid.2014.146
28. Yawalkar N, Ticharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. *J Dermatol Sci* (2009) 54:99–105. doi:10.1016/j.jdermsci.2009.01.003
29. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. Psoriasis is characterized by accumulation of immunostimulatory and TH1/TH17 cell-polarizing myeloid dendritic cells. *J Invest Dermatol* (2009) 129:79–88. doi:10.1038/jid.2008.194
30. Hijnen D, Knol EF, Gent YY, Giovannone B, Bejin SJ, Kupper TS, et al. CD8(+)T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. *J Invest Dermatol* (2013) 133:973–9. doi:10.1038/jid.2012.456
31. Martini E, Wilken M, Cheuk S, Gallais Sereza I, Baharom F, Stahle M, et al. Dynamic changes in resident and infiltrating epidermal dendritic cells in active and resolved psoriasis. *J Invest Dermatol* (2013) 137:865–73. doi:10.1016/j.jid.2016.11.033
32. Tonel G, Conrad C, Laggnier U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. *Immune* (2010) 185:6688–91. doi:10.4049/jimmunol.100138
33. Cheuk S, Martini E, Bergh K, Chang D, Rethi B, Stahle M, et al. Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes. *Exp Dermatol* (2017) 26:824–7. doi:10.1111/exd.13284
34. Cheuk S, Schlums H, Gallais Sereza I, Martini E, Chiang SC, Marquardt N, et al. CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. *Immunity* (2017) 46:287–300. doi:10.1016/j.immuni.2017.01.009
35. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. *Arch Dermatol Res* (2007) 299:359–66. doi:10.1007/s00403-006-0775-4
36. Kim TG, Kim DS, Kim HP, Lee MG. The pathophysiological role of dendritic cell subsets in psoriasis. *BMB Rep* (2014) 47:60–8. doi:10.5483/ BMBRep.2014.47.2.014
37. Renn CN, Sanchez DJ, Ochoa MT, Legaspi AJ, Oh CK, Liu PT, et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. *J Immunol* (2006) 177:298–305. doi:10.4049/jimmunol.177.1.298
38. Takeuchi J, Watari E, Shinya E, Norose Y, Matsumoto M, Seya T, et al. Down-regulation of toll-like receptor expression in monocyte-derived Langerhans
cell-like cells: implications of low-responsiveness to bacterial components in the epidermal Langerhans cells. Biochem Biophys Res Commun (2003) 307:67–74. doi:10.1016/S0006-291X(03)01022-2
39. van der Aar AM, Sylva-Steendam RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MR. Loss of TLR2, TLR4, and TLR5 in Langerhan cells abolishes bacterial recognition. J Immunol (2007) 178:1986–90. doi:10.4049/jimmunol.178.4.1986
40. Seneschal J, Clark RA, Gehad A, Baecker-Allan CM, Kupper TS. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity (2012) 36:873–84. doi:10.1016/j.immuni.2012.03.018
41. Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res (2012) 304:15–22. doi:10.1007/s00403-011-1189-x
42. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of regulated genes and comparisons with in vitro models. J Invest Dermatol (2002) 119:8–10. doi:10.1046/j.1365-2133.2002.48884.x
43. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science (2009) 324:1190–2. doi:10.1126/science.1171700
44. Paulino LC, Tseng CH, Strober BE, Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol (2006) 44:2933–41. doi:10.1128/JCM.00785-06
45. Tett A, Pasolli E, Farina S, Truong DT, Porcelli S, Zollo M, et al. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes (2017) 3:14. doi:10.1038/s41522-017-0022-5
46. Acosta-Rodriguez EV, Rivino L, Geginat J, Jaroszay D, Gattorno M, Lanza vecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 8:639–46. doi:10.1038/nmi1467
47. Lamba G, Palanisamy C, Singh T, Shah D, Lal S, Vinnakota K, et al. Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther (2011) 18:78–80. doi:10.1097/MJT.0b013e3181c650c2
48. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D, van Hauwete AE. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVa and methotrexate therapy. Br J Dermatol (1987) 116:661–6. doi:10.1111/j.1365-2133.1987.tb05899.x
49. Gunther C, Stark J, Zimmermann N, Schakel K. Human 6-sulfo LacNaC (slan) dendritic cells are a major population of dermal dendritic cells in steady state and inflammation. Clin Exp Dermatol (2012) 37:169–76. doi:10.1111/j.1365-2230.2011.04213.x
50. Clarke LE, Helm KF, Hennessy J, Bruggeman RD, Clarke JT. Dermal dendritic cells in psoriasis, nummular dermatitis, and normal-appearing skin. J Am Acad Dermatol (2012) 66:98–105. doi:10.1016/j.jaad.2010.12.003
51. Aldhawany HA, Hasby EA. Immunophenotyping of dendritic cells in lesional, perilesional and distant skin of chronic plaque psoriasis. Cell Immunol (2011) 269:115–9. doi:10.1016/j.cellimm.2011.03.015
52. Gordon KB, Bonish BK, Patel T, Leonard CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol (2005) 153:945–53. doi:10.1111/j.1365-2133.2005.06816.x
53. Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE. Impaired Langerhans cell migration in psoriasis. J Exp Med (2006) 203:953–64. doi:10.1084/jem.200605267
54. Erkin G, Uygur Y, Cicek M, Saric B, Korsuk M. Comparison of topical PUVa, PUVa bath, cyclosporin and methotrexate on psoriatic plaques. J Cutan Pathol (2007) 34:213–9. doi:10.1111/j.1600-0560.2006.00591.x
55. Rek E. Reduction of Langerhans cells in human epidermis during PUVa therapy: a morphometric study. J Invest Dermatol (1982) 78:488–92. doi:10.1111/j.1523-1747.ep12501257
56. Hendriks AG, van der Velden HM, Wolberink EA, Seyger MM, Schalkjew J, Zeeuwen PL, et al. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. Br J Dermatol (2014) 170:571–80. doi:10.1111/bjd.12705
57. Psacino S, Zattra E, Michelotto A, Alibac M. Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: a pilot study. Acta Histochem (2013) 115:767–9. doi:10.1016/j.acthis.2013.02.013
58. Lowes MA, Chaman F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 102:19057–62. doi:10.1073/pnas.0509736102
59. Shaw FL, Cumberbatch M, Kleyn CE, Begum R, Dearman RJ, Kimber I, et al. Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol (2010) 130:1940–2. doi:10.1038/jid.2010.37
60. Eaton LH, Mellody KT, Pikington SM, Dearman RJ, Kimber I, Griffiths CEM. Impaired Langerhans’ cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17. Br J Dermatol (2017) 177:1612–22. doi:10.1111/bjd.14172
LCs in Psoriasis

86. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougerolles A, et al. Cytokines in psoriasis. J Invest Dermatol (2015) 139:157–67. doi:10.1038/jid.2015.120

87. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Epidermal CD1a+ dendritic cell populations in the flaky skin mutant mouse. J Invest Dermatol (2015) 139:286–97. doi:10.1038/jid.2014.313

88. Cheuk S, Wiken M, Blomqvist L, Nylen S, Talme T, Stahle M, et al. Epidermal dendritic cell marked by CD5 is associated with the development of inflammatory and hyperplastic dermatoses. J Dermatol Sci (2017) 88:135–41. doi:10.1016/j.jdermsci.2017.05.003

89. Ramirez-Bosca A, Martinez-Ojeda L, Valcuende-Cavero F, Castells-Rodellas M, Controls on IL-17+ T cell differentiation in mouse and human psoriasis. J Immunol (2014) 193:6215–27. doi:10.4049/jimmunol.1301281

90. Suzuki H, Wang B, Shivi GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modulator, induces migration of Langerhans cells. J Invest Dermatol (2000) 114:135–41. doi:10.1046/j.1523-1747.2000.00833.x

91. Xiao C, Zhu Z, Sun S, Gao J, Fu M, Liu Y, et al. Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis. J Cutan Med Surg (2015) 19:146–52. doi:10.1007/s12290-014-0432-1

92. Matos TR, O’Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol (2013) 190:2544–53. doi:10.4049/jimmunol.1202399

93. Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, et al. Reduced CD8 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol (2013) 190:2544–53. doi:10.4049/jimmunol.1202399

94. Simon JC, Dittmar HC, de Roche R, Wilting J, Christ B, Schopf E. Rapid induction or reproduction is permitted which does not comply with these terms.

95. Bjercke S, Elgo J, Braathen L, Thorsby E. Enriched epidermal Langerhans cells in psoriatic skin suggest their involvement in the pathogenesis of psoriasis. Br J Dermatol (2003) 148:427–33. doi:10.1046/j.1365-2133.2003.05687.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Eidsmo and Martini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 300

8